Shak­ing up Chi­na's PD-(L)1 re­im­burse­ment land­scape, In­novent, Eli Lil­ly earn cov­et­ed spot on na­tion­al cov­er­age

In­novent and Eli Lil­ly have claimed the first-ever spot for a PD-(L)1 in­hibitor on Chi­na’s Na­tion­al Re­im­burse­ment Drug List — at a steep dis­count price that could al­ter the mar­ket land­scape for every oth­er check­point drug in the coun­try.

Start­ing in 2020, Tyvyt will be avail­able for RMB2843 ($403) per 100mg, down about 64% from its orig­i­nal price of RMB7838/100mg ($1117.96).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA